528 related articles for article (PubMed ID: 30777137)
21. Impact of Selective Immunosuppressive Therapy on Subsequent Immune-Related Adverse Events After Immune Checkpoint Inhibitor-Induced Colitis Treatment.
Pizuorno Machado A; Shatila M; Glitza Oliva IC; Altan M; Siddiqui B; Zhou Y; Varatharajalu K; Zhang HC; Thomas A; Wang Y
Am J Clin Oncol; 2023 Aug; 46(8):360-365. PubMed ID: 37219360
[TBL] [Abstract][Full Text] [Related]
22. [Efficacy and Management of Adverse Events of Ipilimumab Including Combination Therapy with Nivolumab].
Uhara H; Itakura E
Gan To Kagaku Ryoho; 2019 Jun; 46(6):1017-1026. PubMed ID: 31273168
[TBL] [Abstract][Full Text] [Related]
23. Inflammation-induced hypoparathyroidism triggered by combination immune checkpoint blockade for melanoma.
Trinh B; Sanchez GO; Herzig P; Läubli H
J Immunother Cancer; 2019 Feb; 7(1):52. PubMed ID: 30791949
[TBL] [Abstract][Full Text] [Related]
24. Ipilimumab-induced toxicities and the gastroenterologist.
Cheng R; Cooper A; Kench J; Watson G; Bye W; McNeil C; Shackel N
J Gastroenterol Hepatol; 2015 Apr; 30(4):657-66. PubMed ID: 25641691
[TBL] [Abstract][Full Text] [Related]
25. Fatal myositis and spontaneous haematoma induced by combined immune checkpoint inhibitor treatment in a patient with pancreatic adenocarcinoma.
Liu Y; Liu Z; Zeng X; Bai C; Chen L; Lin S; Tian X
BMC Cancer; 2019 Dec; 19(1):1193. PubMed ID: 31805889
[TBL] [Abstract][Full Text] [Related]
26. Checkpoint Inhibitor-Induced Colitis.
Bellaguarda E; Hanauer S
Am J Gastroenterol; 2020 Feb; 115(2):202-210. PubMed ID: 31922959
[TBL] [Abstract][Full Text] [Related]
27. Ipilimumab and Nivolumab induced steroid-refractory colitis treated with infliximab: A case report.
Nassri AB; Muenyi V; AlKhasawneh A; Ribeiro BS; Scolapio JS; Malespin M; de Melo SW
World J Gastrointest Pharmacol Ther; 2019 Jan; 10(1):29-34. PubMed ID: 30697447
[TBL] [Abstract][Full Text] [Related]
28. Balancing the Checkpoint: Managing Colitis Associated with Dual Checkpoint Inhibitors and High-Dose Aspirin.
Hammami MB; Gill R; Thiruvengadam N; Oh DY; Beck K; Mahadevan U; Kattah MG
Dig Dis Sci; 2019 Mar; 64(3):685-688. PubMed ID: 30778872
[No Abstract] [Full Text] [Related]
29. Hepatotoxicity After Immune Checkpoint Inhibitor Therapy in Melanoma: Natural Progression and Management.
Huffman BM; Kottschade LA; Kamath PS; Markovic SN
Am J Clin Oncol; 2018 Aug; 41(8):760-765. PubMed ID: 28749795
[TBL] [Abstract][Full Text] [Related]
30. Nivolumab-induced diabetes mellitus-a case report with literature review of the treatment options.
Daetwyler E; Zippelius A; Danioth S; Donath MY; Gut L
Front Immunol; 2023; 14():1248919. PubMed ID: 37965350
[TBL] [Abstract][Full Text] [Related]
31. Granulomatous colitis in a patient with metastatic melanoma under immunotherapy: a case report and literature review.
Sakellariou S; Zouki DN; Ziogas DC; Pouloudi D; Gogas H; Delladetsima I
BMC Gastroenterol; 2021 May; 21(1):227. PubMed ID: 34011268
[TBL] [Abstract][Full Text] [Related]
32. Gastrointestinal complications in patients treated with ipilimumab and nivolumab combination therapy or monotherapy.
Irwin DE; Davis B; Bell JA; Galaznik A; Garcia-Ribas I
J Comp Eff Res; 2019 Jan; 8(2):81-90. PubMed ID: 30547675
[TBL] [Abstract][Full Text] [Related]
33. [Hepatic and digestive adverse events of immune checkpoint inhibitors (anti-CTLA-4 and, anti-PD-1/PD-L1): A clinico-pathological review].
Papouin B; Mussini C; De Martin E; Guettier C
Ann Pathol; 2018 Dec; 38(6):338-351. PubMed ID: 30143243
[TBL] [Abstract][Full Text] [Related]
34. Early administration of infliximab for severe ipilimumab-related diarrhea in a critically ill patient.
Merrill SP; Reynolds P; Kalra A; Biehl J; Vandivier RW; Mueller SW
Ann Pharmacother; 2014 Jun; 48(6):806-10. PubMed ID: 24651165
[TBL] [Abstract][Full Text] [Related]
35. Frequency and imaging features of abdominal immune-related adverse events in metastatic lung cancer patients treated with PD-1 inhibitor.
Alessandrino F; Sahu S; Nishino M; Adeni AE; Tirumani SH; Shinagare AB; Awad MM
Abdom Radiol (NY); 2019 May; 44(5):1917-1927. PubMed ID: 30790009
[TBL] [Abstract][Full Text] [Related]
36. Acute fatal myocarditis after a single dose of anti-PD-1 immunotherapy, autopsy findings: a case report.
Hardy T; Yin M; Chavez JA; Ivanov I; Chen W; Nadasdy T; Brodsky SV
Cardiovasc Pathol; 2020; 46():107202. PubMed ID: 32062109
[TBL] [Abstract][Full Text] [Related]
37. Topical beclometasone dipropionate in the management of immune checkpoint inhibitor-induced microscopic colitis.
Ibraheim H; Green M; Papa S; Powell N
BMJ Case Rep; 2019 Apr; 12(4):. PubMed ID: 30948391
[TBL] [Abstract][Full Text] [Related]
38. Autoimmune Bell's Palsy Following Immunotherapy For Metastatic Melanoma: A Report of 2 Cases.
Zieman D; Frankel AE
J Immunother; 2019 Oct; 42(8):318-320. PubMed ID: 31318723
[TBL] [Abstract][Full Text] [Related]
39. Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review.
Friedman CF; Proverbs-Singh TA; Postow MA
JAMA Oncol; 2016 Oct; 2(10):1346-1353. PubMed ID: 27367787
[TBL] [Abstract][Full Text] [Related]
40. Immune checkpoint inhibitor-induced diarrhea: Clinicopathological study of 11 patients.
Yanai S; Nakamura S; Kawasaki K; Toya Y; Akasaka R; Oizumi T; Ishida K; Sugai T; Matsumoto T
Dig Endosc; 2020 May; 32(4):616-620. PubMed ID: 31595568
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]